TransMedics Group, Inc.

NasdaqGM TMDX

TransMedics Group, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD 37.44 M

TransMedics Group, Inc. Operating Cash Flow is USD 37.44 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 247.61% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

TransMedics Group, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -25.37 M, a 47.62% change year over year.
TransMedics Group, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -48.43 M, a -64.99% change year over year.
TransMedics Group, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -29.35 M, a 3.41% change year over year.
TransMedics Group, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -30.39 M, a 2.41% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqGM: TMDX

TransMedics Group, Inc.

CEO	Dr. Waleed H. Hassanein M.D.
IPO Date	May 2, 2019
Location	United States
Headquarters	200 Minuteman Road
Employees	584
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Key trends

Past 5 years